- Home
- INMD vs EVMN Comparison
INMD vs EVMN Comparison
Compare INMD & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMD | EVMN |
|---|---|---|
| Founded | 2008 | 2020 |
| Country | Israel | United States |
| Employees | N/A | 48 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 842.0M | 825.5M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | INMD | EVMN |
|---|---|---|
| Price | $13.80 | $22.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $17.33 | ★ $43.88 |
| AVG Volume (30 Days) | ★ 768.1K | 341.8K |
| Earning Date | 05-06-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.74 | N/A |
| Revenue Next Year | $3.26 | N/A |
| P/E Ratio | $10.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.72 | $13.89 |
| 52 Week High | $16.74 | $33.20 |
Technical Indicators
Market Signals| Indicator | INMD | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 44.92 | 45.97 |
| Support Level | $13.27 | $21.39 |
| Resistance Level | $13.87 | $23.08 |
| Average True Range (ATR) | 0.32 | 1.43 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 47.03 | 45.87 |
Price Performance
Historical ComparisonAbout INMD InMode Ltd.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.